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Abstract 
Background: Multimodal nanomaterials are useful for providing enhanced diagnostic information simultaneously 
for a variety of in vivo imaging methods. According to our research findings, these multimodal nanomaterials offer 
promising applications for cancer therapy.
Results: Melanin nanoparticles can be used as a platform imaging material and they can be simply produced by 
complexation with various imaging active ions. They are capable of specifically targeting epidermal growth factor 
receptor (EGFR)‑expressing cancer cells by being anchored with a specific antibody. Ion‑doped melanin nanoparticles 
were found to have high bioavailability with long‑term stability in solution, without any cytotoxicity in both in vitro 
and in vivo systems.
Conclusion: By combining different imaging modalities with melanin particles, we can use the complexes to obtain 
faster diagnoses by computed tomography deep‑body imaging and greater detailed pathological diagnostic infor‑
mation by magnetic resonance imaging. The ion‑doped melanin nanoparticles also have applications for radio‑diag‑
nostic treatment and radio imaging‑guided surgery, warranting further proof of concept experimental.
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Background
Nanomaterials with a diameter between 1 and 100  nm 
show unique properties that are distinct from both mol-
ecules and bulk solids. Over the past decade, an explo-
sive amount of novel nanoparticle-based imaging agents 
has been applied to bio-medical sciences [1, 2]. Mag-
netic, gold, radio-isotope embedded, and fluorescent 
nanoparticles have been developed as cancer-imaging 
contrast agents for non-invasive magnetic resonance 
imaging (MRI), X-ray computed tomography (CT), posi-
tron emission tomography (PET), single-photon emis-
sion CT (SPECT), and optical imaging [3–5]. However, 
most contrast agents only have a single imaging modality, 
which has intrinsic limitations such as insufficient sen-
sitivity or spatial resolution, making it difficult to obtain 
accurate and reliable information at the disease site [6, 
7]. To overcome these limitations, a multi-modal imag-
ing material would be able to compensate for the limi-
tations of materials with only a single imaging modality 
provide more detailed information on the interest site [8, 
9]. For example, dual imaging data from MRI and PET 
can corroborate the pathologic state of muscle, vascular, 
and neural tissues, and accurately identify the location of 
abnormal tissues or cells in the body [10]. Although some 
multimodal imaging enabled inorganic particles have 
been developed, their application remains limited in the 
clinical setting because of complicated preparation steps 
and/or their acute toxicity potential [11, 12]. Naturally, 
organic nanomaterials, incorporated with imaging active 
ions are suggested as a superior imaging agent carrier. 
With regard to ions,  Fe3+ can efficiently cause the lon-
gitudinal (T1) decrease of water protons for T1-weighted 
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(T1-w) MR contrasting [13–16]. Bismuth (Bi), which has 
a relatively low toxicity, has been proposed as a good con-
trast agent candidate for indirectly ionizing X-ray radia-
tion imaging tools such as CT due to its high density [17]. 
Directly ionizing gamma-radiation from radioisotopes 
such as 99mTc can also provide real-time information dur-
ing minimally invasive surgeries using a portable detector 
such as Geiger–Müller devices [18]. Furthermore, both 
beta and gamma-ray irradiation radionuclides like 131I 
can be simultaneously applied for radiotherapy by beta-
ray irradiation and for conducting imaging diagnosis 
using the beta or gamma-ray by SPECT, gamma camera, 
or PET [19–21].
Here, we elucidate our findings on bio-inspired mela-
nin nanoparticles (MNPs), which are optimized for 
cation loading, as imaging probes. The prepared mul-
timodal imaging MNP platform doped simultaneously 
with  Fe3+,  Bi3+, and iodine was tested for improving the 
performance of triple imaging by MRI, CT, and SPECT. 
To increase biological efficiency, the MNP surface was 
chemically modified with a poly(ethylene glycol) (PEG) 
linker compound to enhance solution stability, and a can-
cer-specific antibody to actively target cells of interest. As 
proof of concept, the versatile ion-doped MNP (iMNP) 
was used against human hepatocellular carcinoma (HCC) 
target in vitro and in an in vivo system.
Methods
Synthesis and functionalization of iMNP
Dopamine hydrochloride (180  mg) was dissolved in 
90  mL deionized water and then 1  N NaOH (780  μL) 
was added to the solution during vigorous stirring at 
50  °C. The solution quickly turned dark brown. After 
5 h, the black colored MNP solution was centrifuged at 
18,000  rpm for 20  min and then washed several times 
with deionized water for elimination of excess chemi-
cals. The MNP solution was then subjected to the 
ion doping process. To coordinate the  Fe3+ ion, 4  mL 
Fe(NO3)3·6H2O (5.7  mM) solution was mixed with 
10  mL of the MNP dispersion solution (5  mg/mL). 
After stirring for 10  min, the mixture were centrifuged 
(10  min at 20,000  rpm), and the unbound  Fe3+ ions in 
the supernatant were quantitatively estimated in order 
to determine the overall loading capacity. Sequentially, 
Bi(NO3)3·6H2O (4  mL, 5.7  mM) and I–Cl solutions 
(50 μL, 8 mM) from the IODO-GEN® (Additional file 1: 
Fig. S1) were mixed with Fe-doped MNP solution (5 mg/
mL). Similarly, the treated particles were purified by cen-
trifugation and washing with deionized water. The load-
ing capacity and ion-releasing ability from the iMNPs 
were determined by measuring the ion concentration of 
the supernatant after centrifugation (20,000 rpm, 5 min) 
of iMNP solution by ICP-AES. For aqueous solution sta-
bility and selectivity, sulfhydryl (-SH) EGFR antibody 
(Abcam, Anti-EGFR antibody [2E9], ab8465) modified 
by Traut’s reagent was treated with the iMNP solution 
overnight at 4  °C. After centrifugation of the solution 
(5 min at 18,000  rpm) to remove unreacted antibodies, 
2 mL PEG-SH (2 kDa, 0.5 mM) solution was added and 
reacted for 1 h at room temperature. After the reaction’s 
completion, the excess PEG-SH was removed by cen-
trifugation (5 min at 18,000 rpm). The antibody from the 
iMNP-EGFR preparation was quantitatively analyzed 
for protein concentration by BCA protein assay. For the 
SPECT imaging study, borosilicate test tubes coated 
with 50  μg iodination reagent (IODO-GEN®, Thermo 
Scientific) were used for oxidation and incubated with 
148  KBq of carrier-free  Na131I (Korea Atomic Energy 
Research Institute) at room temperature until the color 
changed to yellow (~  10  min). The solution was then 
added to a dispersion of Fe- and Bi-doped MNP (2.5 mg) 
in 10  mM HEPES with rapid agitation by vortexing. 
From this step forward, the samples were protected 
from light with aluminum foil. Unbound iodide-131 was 
removed by centrifugation (18,000 rpm, 15 min) and the 
precipitated product was dispersed in 1 mL PBS buffer. 
The fresh particle solution was administered to the 
mouse liver cancer model as soon as possible.
In vitro phantom MRI/CT study
For the T1-w MR phantom study, various concentrations 
(0–9.6 mM, [Fe], [Bi], [Gd], or [I]) of iMNP-EGFR parti-
cles or  Gadovist® were prepared by introduction into a 
0.5% agarose gel (1:1 volume ratio). To test in vitro phan-
tom MR/CT imaging, a 3 μM concentration of the par-
ticles were incubated with various cells for 1  h inside a 
5%  CO2 incubator. The excess particles were removed 
gently by washing the cell culture with the culture media, 
and the treated cells were detached by trypsinization and 
subsequently centrifuged at 3000 rpm (5 min). All T1-w 
in vitro MR images were acquired on a 3.0-T clinical MR 
scanner (Philips medical system, Netherlands, archieva 
Release 3.2.1.0 version). Axial T1-w images were obtained 
with a TR at 400 ms, a TE at 10 ms, a 240 × 240 matrix, 
a flip angle at 90°, a slice thickness of 3 mm, number of 
averages with 4, bandwidth at 115 Hz/pixel, and an FOV 
of 120 × 120 mm. For CT phantoms, the used MR phan-
toms samples were transferred to the CT imaging scan-
ner. The CT values (called Houndsfield units, Hus) with 
different concentrations of iMNPs were measured on an 
Inveon™ CT system (Siemens Healthcare, Germany). 
In  vitro cellular CT imaging studies were performed 
using the above system as well as the equipment param-
eters of 80 kV and 400 μA.
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Cell toxicity assessment
A MTT assay kit (Invitrogen) was used to evaluate the 
cell viability after treatment with the MNP-based par-
ticles. The various cells were treated with various con-
centrations of the particles and culture times. Cells were 
maintained at 37 °C in a 5%  CO2 incubator. The cells were 
washed, trypsinized, and re-suspended in the culture 
medium. The cells were then seeded at a concentration 
of 5000  cells/well in a 96-well tissue culture plate and 
allowed to grow overnight in a  CO2 incubator. To deter-
mine the cell viability, the culture medium was replaced 
with the MTT solution. After 3  h of incubation inside 
a  CO2 incubator, a specific MTT solution was added to 
dissolve the resulting formazan crystals. The cell viability 
was determined spectrophotometrically at 570 nm, with 
a background subtraction at 690 nm.
Animal preparation
Male 6-week-old BALB/c nude mice were purchased 
from Orient Bio (Seoul, Korea). All animal studies were 
approved by the institutional Animal Care and Use Com-
mittee of Samsung Biomedical Research Institute (Seoul, 
Korea). Orthotropic liver tumor model was created using 
human hepatocellular carcinomas (HCC) liver tumor 
cell line (HepG2, Korean Cell Line Bank). After mice 
were anesthetized by inhaling 2% isoflurane in a mixture 
of  O2/N2 gas (3:7 ratio) with a facemask, the liver was 
exposed. 1 × 106 HepG2 cells suspended in 10 μL HBSS 
with Matrigel (1:1) were then slowly injected into the 
liver. After 4 weeks, tumor size was checked using MRI. 
The same anesthetic technique was used for obtaining 
MR images.
In vivo MRI imaging
In this study, all mice were anesthetized using 2% iso-
flurane during the entire experiment (MRI, CT, and 
SPECT). MR images were acquired through a fast spin-
echo T1-w MRI sequence by using the 7-T MRI system 
(Bruker Biospin, Fällanden, Switzerland), with the follow-
ing parameters with respiratory gating: repetition time 
(TR)/echo time (TE) = 370/7.6 ms, echo train length = 2, 
100 × 100 μm2 in-plane resolution with a slice thickness 
of 1 mm, and 14 slices. A quadrature volume coil (35 mm 
i.d.) was used for excitation and receiving the signal.
In vivo Micro‑CT/SPECT imaging
This study used the small animal integrated CT/SPECT 
imaging and analysis system (Inveon™ Micro-CT/SPECT 
multimodality system, Siemens Healthcare, Germany), 
which is designed as an in  vivo system. The HCC liver 
implanted mice were intravenously injected with 200 μL 
of the iMNP-EGFR dispersion (148 KBq 131I, 0.3 μmol Fe, 
and 0.27 μmol Bi per 0.1 mg MNP/mL). All samples were 
scanned with 1.5 mm aluminum filter, using the follow-
ing settings: 360° total rotation and 360 rotation steps, 1° 
step size, 70 kV and 400 µA source setting, and 700 ms 
exposure time per step. Pixels were binned by 4, resulting 
in an effective pixel size or resolution of approximately 
74.93  µm. For each scan, the dataset was reconstructed 
with a down sample factor of 2 using the Inveon Acquisi-
tion Workplace software package (IAW, Siemens Medical 
Solutions, Knoxville, TN, USA), implementing the modi-
fied Feldkamp filtered back projection algorithm (Shepp-
Logan filter). Afterwards, the reconstructed images were 
imported using the Inveon™ Research Workplace (IRW) 
into the accompanying two-dimensional (2D) and three-
dimensional (3D) biomedical image analysis software 
package (IRW, CT Bone Visualization and Analysis, Sie-
mens Medical Solutions, Knoxville, TN, USA) for visu-
alization and analysis. For the SPECT imaging, SPECT 
scans were acquired using an Inveon™ micro-SPECT 
imaging system. SPECT images were obtained with 
high-resolution parallel hole collimators and the pulse-
height analyzer window set over the 30 keV photopeak of 
iodine-131. In vivo CT imaging studies were performed 
using the same in  vitro CT measurement parameters 
(80 kV and 400 μA).
In vivo toxicological study
Male mice were housed in stainless steel cages containing 
sterile paddy husk as bedding in ventilated animal rooms. 
They were acclimated in the controlled environment 
(Temp.: 22 ±  1  °C, humidity: 60 ±  10% and light: 12  h 
light/dark cycle) with free access to water and a commer-
cial laboratory complete food. The 100 μL PBS (control), 
MNP and iMNP-EGFR solutions were administrated 
daily via intraperitoneal injection for each of five mice 
with 0.5 mg concentration of particle after adaption. The 
treated mice were measured for body weight change over 
15 days. After daily treatment for 2 weeks, the mice were 
harvested and various organs were analyzed for weight 
change and tissue morphology by hematoxylin and eosin 
(H&E) staining.
Results and discussion
Preparation of MNP and ions doping
The MNPs were synthesized successfully by neutraliza-
tion and spontaneous air oxidation of dopamine hydro-
chloride as previously reported [22]. Briefly, 1 N NaOH 
solution was added into the dopamine hydrochloride 
solution under vigorous stirring to facilitate spontane-
ous oxidation and polymerization processes that formed 
the spherical MNPs. The particles were purified by wash-
ing with distilled water and centrifugation several times. 
From the transmission electron microscopy (TEM) anal-
ysis, the prepared MNPs showed an average diameter of 
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100  nm with a regular size distribution. The MNPs are 
comprised of 5,6-dihydroxyindole (catechol types) which 
were generated to form the coordination complexes with 
positive ions (Fig.  1a). Subsequently, sulfhydryl EGFR 
antibody and methoxy-poly(ethylene glycol) (PEG-SH) 
were introduced onto the particle surface by linkage via 
a Schiff’s base or Michael addition reaction (Fig. 1b) [23]. 
Using the MNP’s catechol groups, the  Fe3+ and  Bi3+ ions 
were simultaneously coordinated, and facilitated aro-
matic substitution reactions for  I+ ion linkage onto the 
MNP surface. Morphology was characterized, and quali-
tative analysis was performed by scanning transmission 
electron microscopy (STEM). Generally, iodine radio-
isotopes (I*) such as 125I or 131I are purchased in their 
radio-iodide form, NaI*. However, the negative ion form 
of the radio-iodide chelated ineffectively with the cat-
echol group of the prepared MNP due to charge repul-
sion. Therefore, we optimized the preparation of iodine 
MNPs using an iodination tube (Additional file 1: Fig. S1) 
that could produce the positive iodous ions  (I+). Within 
5  min, the NaI* (colorless solution) turned pale yellow 
(I*–Cl) and the positive iodous ions were easily substi-
tuted onto the MNP. From Fig.  1c, it can be seen that 
the various positive ions were present on the surface of 
the iMNP and were significantly different from the non-
doped MNP as determined by energy-dispersive X-ray 
spectrometer (EDS) equipped STEM (Additional file  1: 
Fig. S2). To determine the loading capacity of the various 
Fig. 1 Schematic for the preparation of various ions chelating onto the melanin nanoparticle (iMNP, a), and surface modification with antibody and 
pegylation (b). Chelated  Fe3+,  Bi3+, and  I+ ions were exhibited on the surface of iMNP by STEM (c)
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positive ions, all ions were saturated at similar the con-
centration of 2.5–2.7  μmol in the 1  mL MNP solution 
(1 mg/mL) (Fig. 2a). Fourier transform infrared spectros-
copy (FT-IR) was used to characterize the treated iMNPs 
by observing the change in the chemical functional group 
intensities during the ions complexation (Additional 
file 1: Fig. S3a). The νO–H group peak from the catechol 
decreased and reversely the νM–O showed increased 
vibrating peak intensity. The iMNPs also showed excel-
lent dispersion ability in  H2O, PBS buffer, culture media 
and human serum aqueous solutions for a month, vali-
dating their long-term stability in solution and suitability 
for biological applications (Additional file 1: Fig. S3b). 
In vitro phantom study for MRI and CT
Next, in a phantom study for imaging modalities, the 
iMNP was compared with commercial, clinically used 
T1-w MR  (Gadovist®, Bayer Schering Pharma) and CT 
 (Telebrix®, Guerbet Asia Pacific) imaging agents at the 
same concentration of ions. As a T1-w MRI agent, the 
iMNP solution displayed a 2-fold higher relaxivity than 
 Gadovist® by a 0.47  T magnetic relaxometer (mq-20, 
Bruker), and also, showed 4.5-fold higher Hounsfield 
(HU) intensity than the  Telebrix® solution at the same 
concentration of ions by an X-ray-based CT scan (Fig. 2b 
and Additional file  1: Fig. S4). From the comparative 
study of MR and CT phantoms, the superiority of the 
iMNP as an imaging agent was confirmed, as it can elicit 
the same signal strengths at 2-fold less than half of the 
equivalent dosage. According to the Solomon–Bloem-
bergen–Morgan (SBM) theory predicting the efficiency 
of MRI contrast agents, longitudinal relaxivity (r1) is 
divided into two parts: inner sphere relaxation, which is 
influenced by directly coordinated water molecules, and 
outer sphere relaxation, which arises from interaction 
of the complex with water molecules in the second and 
outer sphere. Although the predominant effect of inner 
sphere relaxation is on r1 relaxivity, experimental studies 
on catechol–Fe3+ complexes of the iMNPs show that the 
interactions between second-sphere water molecules and 
oxygen atoms significantly contribute to their unusually 
high enhancing capabilities as well.
To generate specific targeting ability, epidermal growth 
factor receptor (EGFR) cancer cell specific antibodies 
Fig. 2 Chelating capacity of the various ions onto MNPs by ICP‑AES analysis (a). T1‑w MR (3.0‑T, Philips) and CT (Inveon
™, Siemens) contrast signal 
with different concentrations of ions (in iMNP) for sensitivity measurement (b). Protein quantification of antibodies conjugated onto the iMNP by 
BCA assay (c). Protein levels of various biomarkers concerned with cell organelle function or proliferation for measuring cytotoxicity after treatment 
by Western‑blot analysis (d; i: only cell, ii: iMNP and iii: iMNP‑EGFR; and see Additional file 1: Fig. S5)
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were anchored onto the iMNP surfaces by antibody 
conjugation procedure, and the conjugated iMNP and 
EGFR antibody (iMNP-EGFR) preparation was quanti-
fied by a BCA protein assay (Fig.  2c). The doped ions 
did not leak from the iMNP under various pH aqueous 
conditions after 72 h of exposure, confirming the safety 
and reproducibility of the imaging agents (Additional 
file  1: Fig. S5a). Cellular toxicity of iMNP after uptake 
by EGFR-positive liver cancer cells (HepG2) was deter-
mined. The cell viability was over 90% under various 
concentrations and incubation times by 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) 
which is a colorimetric assay for assessing cell metabolic 
activity. Their changing expression levels monitored the 
various biomarkers for cellular functions after treatment 
with MNPs, iMNPs, and iMNP-EGFR particles by West-
ern blotting. iMNPs caused a slight but in significant 
decrease in protein expression (Fig.  2d and Additional 
file 1: Fig. S5b and c).
The iMNP-EGFR particles had high selectivity for 
the EGFR-positive liver cancer cells. Red fluorescent 
iMNP-EGFR, prepared after a conjugation reaction, was 
dominantly present in HepG2 cells, as opposed to EGFR-
negative cell lines of NIH-3T3 and MCF7 (Fig.  3a and 
Additional file  1: Fig. S6). Moreover, a Bio-TEM analy-
sis clearly determined that the iMNP-EGFR particles 
were distributed in the HepG2 cell cytosol presumably 
through energy dependent receptor-mediated endocy-
tosis. The cells treated with various MNPs were used for 
T1-w MR (3.0-T, Philips) and CT imaging. In Fig. 3b, after 
treatment and making a cell pellet in a tube, EGFR-neg-
ative cells or non-antibody iMNP-treated cells showed 
similar low contrast intensity, but the iMNP-EGFR-
treated HepG2 liver cancer cells exhibited a distinct high 
contrast signal.
In vivo imaging
Next, we applied our iMNP-EGFR particles to an in vivo 
mouse tumor model. EGFR-positive HepG2 liver can-
cer cells were implanted into the liver, generating an 
orthotopic tumor model that is clinically more relevant 
than the subcutaneous implant model as a xenograft 
tumor model. During acquisition of MRI/CT/SPECT 
data all mice were anesthetizing by 2% isoflurane and 
Fig. 3 Specific targeting of the red‑fluorescent iMNP after EGFR antibody conjugation (a, blue: DAPI nuclear staining and red: iMNP‑EGFR, scale bar: 
20 μm). Bio‑TEM image of EGFR positive HepG2 liver cancer cell morphology after treatment with iMNP‑EGFR (a, right, scale bar: 1 μm, N indicates 
the nucleus). Cellular phantom study data of the T1‑w MR and CT imaging after treatment and accumulation of cells by centrifugation (see “Meth‑
ods”) to confirm selectivity (b)
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the iMNP-EGFR particles were administrated through 
intravenous tail vein injection. In Fig.  4 and Additional 
file 1: Fig. S7, all MRI/CT/SPECT images exhibited high 
general contrast and comparatively the difference in spe-
cific targeting ability of iMNP-EGFR vs iMNP alone was 
expressed by concentrated particles in the liver tumor 
showing exceptional contrast. The preferential tumor 
accumulation of iMNP-EGFR particles resulted from the 
interaction of anchored antibody with tumor receptor 
as an active targeting and also the enhanced permeabil-
ity and retention (EPR) effect during particle circulation. 
The individual images each have diagnostic meaning, 
and compensate for each method’s limitations, greatly 
improving diagnostic accuracy. Using multimodal-
ity offers the advantages of detailed cancer distribution 
information using SPECT imaging and clear location 
marking tumors using anatomical CT or MRI imaging. 
From these results, the rapid CT image suggested the 
possibility of a tumor with low sensitivity, but the addi-
tional MRI image identified the tumor in the liver with 
high resolution, and finally, the SPECT analysis provided 
detailed information about the clearance and distribution 
of particles. As a fundamental toxicological assessment, 
bare MNPs, iMNP-EGFR particles, and phosphate-
buffered saline (PBS) were administered to normal mice 
by intravenous injection, and then monitored for body 
weight change and various organ functions (Additional 
file  1: Fig. S8). From the results, the MNP-treated mice 
did not show significant abnormality for body weight, 
but the color of several organs (especially liver, lung, 
and spleen) became black possibly due to the accumu-
lation of the injected particles. However, after immuno-
histochemical (IHC) staining of the organ tissues, it was 
confirmed that the accumulated MNPs did not affect the 
tissue morphology (Additional file 1: Fig. S9). The iMNPs 
mainly accumulated in the liver, spleen, and lung, but the 
exposed organ tissues did not show any abnormality. Sur-
prisingly, the iMNP-EGFR particles were slightly more 
concentrated in the lung than the other organs. There-
fore, we will further investigate the mechanism of metab-
olism and interaction between melanin and lung tissue.
Conclusion
The synthetic MNP platform, which is similar to that 
of living organisms like natural sepia melanin in cuttle-
fish, has the superior ability to simultaneous complex 
multiple types of positive ions. Moreover, MNPs can be 
simply fabricated and also have their surfaces modified 
with PEGylation and antibody conjugation. The doped 
metal ions were not released by biological environmental 
changes, and the iMNP-EGFR particles did not show sig-
nificant cellular acute toxicity. From the phantom study, 
Fig. 4 iMNP‑EGFR mediated specific multi‑modal imaging in in vivo cancer mouse model using various imaging tools after intravenous injection 
of the particles (a MRI, b micro‑CT, and c micro‑SPECT; see “Methods” section). The left images of a (axial view) and b (coronal view) indicate before 
administration of particle solution, and the right images of a and b are after 24 h of particle injection. In c (coronal projection view), the white arrow 
indicates the implanted HCC tumor in the liver and red indicates the normal lung
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the iMNP-EGFR particle-imaging agent revealed higher 
contrast intensity than a clinically used imaging agent 
in T1-w MRI and CT. The EGFR antibody-conjugated 
iMNPs exhibited specific targeting to EGFR-overex-
pressed liver cancer cell in vitro, as observed by MRI and 
CT imaging. The iMNP-EGFR particles were applied for 
the simultaneous multi-imaging of xenograft liver cancer 
and the successful targeting of EGFR-expressed ortho-
topic tumor in mouse models. Most importantly, admin-
istration of the iMNP imaging contrast agent could be 
clinically applied for the rapid diagnosis of cancer by CT 
scanning. Detailed information can also be gathered by 
MRI for discovering and addressing morphologically and 
functionally pathophysiologic questions. Furthermore, as 
a proof-of-concept experiment, radio imaging using the 
iMNP system exhibited the possibility for its radio-thera-
peutic application by beta-ray irradiation or radio-guided 
surgical treatment using detector tubes. Our findings 
suggest that the iMNP system will be a suitable candi-
date probe for various diagnostic imaging modalities and 
radio-guided treatment tools. In a future study, we will 
perform a detailed in vivo toxicological assessment of the 
iMNPs’ pharmacokinetics, lethal dose calculation, and 
the half maximal effective concentration (EC50) in pre-
clinical practice.
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